Statins are Independently Associated with Increased HbA1c in Type 1 Diabetes

Abstract

AIMS

Statin use has been associated with increased risk of developing type 2 diabetes (T2DM), and with impaired glycemic control in T2DM patients. The association between statin use and glycemic control in type 1 diabetes (T1DM) is unknown. The association between use of statins and glycemic control in T1DM patients without known heart disease was examined.

METHODS

Cross-sectional study of 1093 T1DM patients from the outpatient clinic at Steno Diabetes Center. Physical examination, questionnaires, and echocardiography were performed in all patients. Investigators were blinded to all laboratory measurements. Data were analyzed in uni-and multivariable models.

RESULTS

Mean age 49.6 years, 53% men, mean diabetes duration 25.5 years, 475 (43.5%) received statins. In baseline analyses statin users tended to be older, have longer diabetes duration, and have more severe kidney disease. Left ventricular ejection fraction was not associated with statin use. In multivariable models including age, gender, diabetes duration, BMI, blood pressure, physical activity, family history of cardiovascular disease, physical activity, albuminuria, eGFR, retinopathy, smoking, cholesterol, ejection fraction, triglycerides, and use of ACE/ATII-antagonists, aspirin, calcium-antagonists, betablockers or diuretics, statin use was independently and significantly associated with higher HbA1c (0.2% (95%CI: 0.1;0.4) (2.0 mmol/mol (0.2; 3.), p = 0.029).

CONCLUSIONS

In T1DM, use of statins is independently associated with impaired glycemic control. A causal relationship cannot be determined from this study. Given the benefit on cardiovascular outcome, this should not cause patients to stop statin treatment, but may indicate a need to revisit dose of insulin when starting statin treatment

http://www.diabetesresearchclinicalpractice.com/article/S0168-8227(15)00423-4/abstract

graham64 wrote:
CONCLUSIONS

In T1DM, use of statins is independently associated with impaired glycemic control. A causal relationship cannot be determined from this study. Given the benefit on cardiovascular outcome, this should not cause patients to stop statin treatment, but may indicate a need to revisit dose of insulin when starting statin treatment

How ironic, statins are supposed to decrease risk of CVD but require increased insulin which increases risk of CVD . . .

chris c wrote:

graham64 wrote:
CONCLUSIONS

In T1DM, use of statins is independently associated with impaired glycemic control. A causal relationship cannot be determined from this study. Given the benefit on cardiovascular outcome, this should not cause patients to stop statin treatment, but may indicate a need to revisit dose of insulin when starting statin treatment

How ironic, statins are supposed to decrease risk of CVD but require increased insulin which increases risk of CVD . . .

Yes and of course the use of statins are linked  to a 50% raised risk of Type 2," but benefits still outweigh the risks say the experts 

No no, they're starting to admit statins are NOT the best thing since sliced bread. PCSK9 inhibitors on the other hand, they're the Real Deal! Only $299.99/month at your pharmacy now!!!

chris c wrote:No no, they're starting to admit statins are NOT the best thing since sliced bread. PCSK9 inhibitors on the other hand, they're the Real Deal! Only $299.99/month at your pharmacy now!!!

Hang on Chris the prices you quote must be for an inferior product 

Amgen debuts Repatha in UK, with price at a huge discount to that in USA

Amgen said it would charge £340.20 ($521.70) in the UK for a 28-day supply of Repatha, or roughly $6,780 a year, against a list price of $14,100 in the USA, where the drug is also being launched this week.

http://www.thepharmaletter.com/article/amgen-debuts-repatha-in-uk-with-price-at-a-huge-discount-to-that-in-usa

Four grand a year for decades for a few extra days of life, at the wrong end. What a stunning bargain!